These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32389218)

  • 1. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
    Deverka PA; Douglas MP; Phillips KA
    Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Payer perceptions of the use of real-world evidence in oncology-based decision making.
    Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
    Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS
    Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
    Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
    Timbie JW; Kim AY; Concannon TW
    Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies.
    Sarri G; Hernandez LG
    J Comp Eff Res; 2024 Sep; 13(9):e240061. PubMed ID: 39132748
    [No Abstract]   [Full Text] [Related]  

  • 7. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
    Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
    BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?
    Capkun G; Corry S; Dowling O; Asad Zadeh Vosta Kolaei F; Takyar S; Furtado C; Jónsson P; Kleinermans D; Lambert L; Schiel A; Facey K
    Int J Technol Assess Health Care; 2022 Nov; 38(1):e79. PubMed ID: 36321447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of real-world evidence for oncology clinical decision making in emerging economies.
    Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
    Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
    Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
    CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
    Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
    J Manag Care Spec Pharm; 2017 Jun; 23(6):613-620. PubMed ID: 28530524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world evidence for coverage decisions: opportunities and challenges.
    Hampson G; Towse A; Dreitlein WB; Henshall C; Pearson SD
    J Comp Eff Res; 2018 Dec; 7(12):1133-1143. PubMed ID: 30411972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing Payers' Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment.
    Saldarriaga EM; Hauber B; Carlson JJ; Barthold D; Veenstra DL; Devine B
    Value Health; 2022 Mar; 25(3):443-450. PubMed ID: 35227457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
    Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
    Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.
    Chambers JD; Saret CJ; Anderson JE; Deverka PA; Douglas MP; Phillips KA
    Int J Technol Assess Health Care; 2017 Jan; 33(4):534-540. PubMed ID: 29065945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.
    Zisis K; Pavi E; Geitona M; Athanasakis K
    J Pharm Pharm Sci; 2024; 27():12302. PubMed ID: 38481726
    [No Abstract]   [Full Text] [Related]  

  • 19. The challenges and opportunities in using real-world data to drive advances in healthcare in East Asia: expert panel recommendations.
    Crane G; Lim JCW; Gau CS; Xie J; Chu L
    Curr Med Res Opin; 2022 Sep; 38(9):1543-1551. PubMed ID: 35786170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical integration of next generation sequencing: coverage and reimbursement challenges.
    Deverka PA; Dreyfus JC
    J Law Med Ethics; 2014; 42 Suppl 1(Suppl 1):22-41. PubMed ID: 25298289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.